Business Trends

Apr 01, 2005
BioPharm International
By BioPharm International Editors
Out-licensing has become a crucial part of most biotech companies' business strategies.
Apr 01, 2005
BioPharm International
By BioPharm International Editors
With biotech valuations at the lowest point in years, the resulting investment opportunities are multiplying — seemingly by the hour.
Apr 01, 2005
BioPharm International
By BioPharm International Editors
Biotechnology and life sciences companies come in all shapes and sizes. Some are multinational companies with vast resources and others are small companies working with a few new compounds. Regardless of size or market position, these companies should all have one common question of those that handle their insurance: Will their current insurance program protect their assets and investments in the event of a significant loss? Understanding the nature of risks, acquiring suitable insurance, and comprehending policy issues when claims arise are essential to protecting assets and obtaining reimbursement when losses occur.
Apr 01, 2005
BioPharm International
By BioPharm International Editors
Outsourcing is becoming increasingly widespread and essential in the biopharmaceutical industry. Its imprint on biotech world business and on the development of biopharmaceutical drugs is becoming ever more pronounced. It is estimated that almost one-half of biopharmaceutical companies contract out at least part of the production of their products. On the other hand, those companies that do not outsource production often contract out some of their development activities.
Mar 01, 2005
BioPharm International
By BioPharm International Editors
A tepid currency picture may cause biopharm companies to put the breaks on initiatives in places like information systems, research and development, and even hiring.
Mar 01, 2005
BioPharm International
Revisiting simple, robust, and controllable technology is the only way to overcome these challenges.
Mar 01, 2005
BioPharm International
Pharmaceutical companies today are faced with increased costs for drug discovery and development and aggressive competition from generic drug companies. As research costs skyrocket, generic drug companies sit poised and ready to compete as soon as a patent expires. Maximizing patent term for successful products is an effective strategy for fending off generic competition and extending product lifecycle. This article will explore strategies for keeping a product under the patent umbrella.
Feb 01, 2005
BioPharm International
By BioPharm International Editors
I wrote in the December 2005 issue of Streetalk that no matter who won the election between George Bush and John Kerry, the result would have been good news to the biopharm industry - if for different reasons. I said that with President Bush back in office for a second term, industry red tape would be diminished and the life sciences sector would shift into higher gear.
Feb 01, 2005
BioPharm International
By BioPharm International Editors
Speed of response, small-scale manufacturing and process flexibility will become increasingly important.
Jan 01, 2005
BioPharm International
By BioPharm International Editors
For years, the pharmaceutical sector has provided a safe haven for investors. I'm not so sure that will be the case in 2005.
native1_300x100
lorem ipsum